statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics to Participate at Upcoming Investor Conferences PR Newswire WARREN, N.J., May 2, 2024 WARREN, N.J., May 2, 2024...

PTC Therapeutics to Participate at Upcoming Investor Conferences

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results PR Newswire...

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results PR Newswire SOUTH...

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results

PTC Therapeutics, Inc. (NASDAQ:PTCT  Get Free Report) has been given a consensus recommendation of Reduce by the thirteen analysts that are presently covering the company...

PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Recommendation of "Reduce" by Brokerages

PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA PR Newswire SOUTH PLAINFIELD, N.J., March 28, 2024...

PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA

PTC Therapeutics (NASDAQ:PTCT  Get Free Report) had its target price raised by equities research analysts at Jefferies Financial Group from $33.00 to $35.00 in a report issued on Wednesday...

PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $35.00 at Jefferies Financial Group

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

ClearPoint congratulates partner PTC Therapeutics on completion of its BLA

PTC Therapeutics Provides Key Regulatory Updates PTC Therapeutics Provides Key Regulatory Updates PR Newswire SOUTH PLAINFIELD, N.J., March 19, 2024 -BLA submitted to FDA for Upstaza for the...

PTC Therapeutics Provides Key Regulatory Updates

This is a Bearish indicator signaling PTCT's price could decline from here. Traders may explore shorting the stock or put options...

PTC Therapeutics (PTCT, $29.58) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 15, 2024

This is a signal that PTCT's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

PTC Therapeutics (PTCT, $28.91) Stochastic Oscillator left the overbought zone on March 14, 2024

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Volume	174,742.00
52-Wk High	$59.84
52-Wk Low	$17.53

Period	Estimated	Reported	Surprise	Result
Q2'24	-$1.26	--	--	N/A
Q1'24	-$1.27	-$1.20	5.86%	BEAT
Q4'23	$0.49	-$2.06	-522.17%	MISSED
Q3'23	-$1.06	-$1.76	-65.26%	MISSED
Q2'23	-$1.62	-$2.66	-64.06%	MISSED

PTCT PTC Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals